Cardiovascular microphysiological systems (CVMPS) for safety studies – a pharma perspective
- 15 January 2021
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 21 (3), 458-472
- https://doi.org/10.1039/d0lc01040e
Abstract
The integrative responses of the cardiovascular (CV) system are essential for maintaining blood flow to provide oxygenation, nutrients, and waste removal for the entire body. Progress has been made in independently developing simple in vitro models of two primary components of the CV system, namely the heart (using induced pluripotent stem-cell derived cardiomyocytes) and the vasculature (using endothelial cells and smooth muscle cells). These two in vitro biomimics are often described as immature and simplistic, and typically lack the structural complexity of native tissues. Despite these limitations, they have proven useful for specific “fit for purpose” applications, including early safety screening. More complex in vitro models offer the tantalizing prospect of greater refinement in risk assessments. To this end, efforts to physically link cardiac and vascular components to mimic a true CV microphysiological system (CVMPS) are ongoing, with the goal of providing a more holistic and integrated CV response model. The challenges of building and implementing CVMPS in future pharmacological safety studies are many, and include a) the need for more complex (and hence mature) cell types and tissues, b) the need for more realistic vasculature (within and across co-modeled tissues), and c) the need to meaningfully couple these two components to allow for integrated CV responses. Initial success will likely come with simple, bioengineered tissue models coupled with fluidics intended to mirror a vascular component. While the development of more complex integrated CVMPS models that are capable of differentiating safe compounds and providing mechanistic evaluations of CV liabilities may be feasible, adoption by pharma will ultimately hinge on model efficiency, experimental reproducibility, and added value above current strategies.Keywords
This publication has 104 references indexed in Scilit:
- In Vitro Engineering of Vascularized Tissue SurrogatesScientific Reports, 2013
- Validation of an in vitro contractility assay using canine ventricular myocytesToxicology and Applied Pharmacology, 2012
- Ensembles of engineered cardiac tissues for physiological and pharmacological study: Heart on a chipLab on a Chip, 2011
- Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeysBritish Journal of Pharmacology, 2011
- Detection of multiple cardiac markers with an integrated acoustic platform for cardiovascular risk assessmentAnalytica Chimica Acta, 2011
- Selective Regulation of Cardiac Organic Cation Transporter Novel Type 2 (OCTN2) in Dilated CardiomyopathyThe American Journal of Pathology, 2011
- How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?British Journal of Pharmacology, 2011
- PDE4 inhibitors: current statusBritish Journal of Pharmacology, 2008
- An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary diseaseBritish Journal of Clinical Pharmacology, 2006
- Three-Dimensional In Vitro Reaggregates of Embryonic Cardiomyocytes: A Potential Model System for Monitoring Effects of Bioactive AgentsSLAS Discovery, 2005